Jedd Wolchok, MD, PhD, is currently chief of the Melanoma and Immunotherapeutics Service, associate attending physician at Memorial Sloan Kettering Cancer Center (MSK) with an expertise in the treatment of metastatic melanoma. He is also the Lloyd J. Old Chair for Clinical Investigation. Dr. Wolchok has helped establish MSK as a leader in the discovery and treatment of cancers with novel immunotherapies. He was instrumental in the clinical development leading to the approval of ipilimumab for advanced melanoma. He also leads the MSK Immune Monitoring Facility, a world-renowned full-time core dedicated to the pre-clinical and clinical cellular, serological and pathological monitoring of clinical trials of new immunotherapeutic approaches.
In 2011, he established the Immunotherapeutics Clinical Core, a specialized phase 1-2 outpatient unit at MSK that is focused on the conduct of novel immunotherapy trials, with a specific emphasis on pharmacodynamic biomarker identification. This group treats patients with a broad spectrum of malignancies. He is interested in finding new and improved ways to prevent melanoma from recurring after surgery, focusing his research on the development of innovative ways to use the immune system to treat cancer.
Education & Training
- New York University School of Medicine, MD
- New York University Graduate School of Arts & Sciences, PhD
Awards & Honors
- 2016: Alfred Taubman Prize for Excellence in Translational Medical Research
- 2014: American Association for Cancer Research Richard and Hinda Rosenthal Memorial Award; Giants of Cancer Care in Melanoma Award
- 2013: Virginia and Daniel K. Ludwig Chair for Clinical Investigation
- 2012: Melanoma International Foundation's Doctor of the Year award
- 2011: Director, Cancer Vaccine Collaborative
- 2010: Melanoma Research Foundation – Humanitarian Award
- 2008: Damon Runyon-Lilly Clinical Investigator Award